I would like to add to that point. As a global company, and as a member company of Rx&D, we know that IP is about protecting new ideas. It's about helping us discover the undiscovered. It is about helping us compete globally. It's about helping us bring this research to Canada and about making Canada part of the research continuum. It's putting our footprint on future therapies that will save lives in the world and in Canada.
For us, absolutely, it is an important part of that list of factors our global CEOs deal with.
There is no doubt that with our investment opportunity, there were other affiliates saying, “Whatever Canada does, we're going to match. We will do exactly what they do.” Not all of them have the same policies in place, and that's where we have the advantage. We have policies in place. And we have policies we can improve now that will keep us ahead of the curve and will help us compete with our European affiliates.